The poly(ADP-ribosyl)ation of FoxO3 mediated by PARP1 participates in isoproterenol-induced cardiac hypertrophy

• Published in: Biochimica et biophysica acta 2016-12, Vol.1863 (12), p.3027-3039
• Main Authors: Lu, Jing, Zhang, Renwei, Hong, Huiqi, Yang, Zuolong, Sun, Duanping, Sun, Shuya, Guo, Xiaolei, Ye, Jiantao, Li, Zhuoming, Liu, Peiqing
• Format: Article
• Language: English
• Subjects: Adenoviridae - genetics; Adenoviridae - metabolism; Animals; Animals, Newborn; Benzamides - pharmacology; Benzimidazoles - pharmacology; Cardiac hypertrophy; Cardiomegaly - chemically induced; Cardiomegaly - genetics; Cardiomegaly - metabolism; Cardiomegaly - pathology; Echocardiography; Forkhead Box Protein O3 - genetics; Forkhead Box Protein O3 - metabolism; FoxO3; Genetic Vectors - chemistry; Genetic Vectors - metabolism; Isoproterenol; Male; Myocytes, Cardiac - cytology; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; PARP1; Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors; Poly (ADP-Ribose) Polymerase-1 - genetics; Poly (ADP-Ribose) Polymerase-1 - metabolism; Poly Adenosine Diphosphate Ribose - metabolism; Poly(ADP-ribosyl)ation; Primary Cell Culture; Protein Processing, Post-Translational; Rats; Rats, Sprague-Dawley; Signal Transduction; Transcription, Genetic
• ISSN: 0167-4889; 0006-3002; 1879-2596
• DOI: 10.1016/j.bbamcr.2016.09.019

The Forkhead box-containing protein, O subfamily 3 (FoxO3) transcription factor negatively regulates myocardial hypertrophy, and its transcriptional activity is finely conditioned by diverse posttranslational modifications, such as phosphorylation, acetylation, ubiquitination, methylation and glycosylation. Here, we introduce a novel modification of the FoxO3 protein in cardiomyocytes: poly(ADP-ribosyl)ation (PARylation) mediated by poly(ADP-ribose) polymerase-1 (PARP1). This process catalyzes the NAD+-dependent synthesis of polymers of ADP-ribose (PAR) and their subsequent attachment to target proteins by PARPs. Primary-cultured neonatal rat cardiomyocytes were incubated with isoproterenol (ISO) to induce hypertrophy, or were infected with recombinant adenovirus vectors harboring PARP1 cDNA (Ad-PARP1). Sprague-Dawley (SD) rats were treated with ISO to induce cardiac hypertrophy, or were injected with Ad-PARP1 into the anterior and posterior left ventricular walls. Cardiomyocyte surface area, the mRNA expression of hypertrophic biomarkers, echocardiography, morphometry of the hearts were measured. The PARP1 activity was tested by cellular PAR levels. Interactions of PARP1 and FoxO3 were investigated by co-immunoprecipitation and immunofluorescence technique. PARylation of FoxO3 mediated by PARP1 facilitated its phosphorylation at the T32, S252 and S314 sites, triggered its nucleus export and suppressed its transcriptional activity and target genes expression, ultimately inducing cardiac hypertrophy. Additionally, PARP1 silencing or specific inhibition by 3-Aminobenzamide (3AB) and veliparib (ABT-888) alleviated the inhibition of FoxO3 activity by ISO, thus suppressing ISO-induced cardiac hypertrophy. Our data provide the first evidence that PARP1 exacerbates cardiac hypertrophy by PARylation of FoxO3. [Display omitted] •PARP1 interacts with poly(ADP-ribosyl)ated FoxO3 in NRCMs and in rat heart tissues.•Poly(ADP-ribosyl)ation of FoxO3 facilitates its phosphorylation at three sites.•Poly(ADP-ribosyl)ation of FoxO3 suppresses its transcriptional activity.•PARP1 exacerbates cardiac hypertrophy partially by poly(ADP-ribosyl)ation of FoxO3.